Analysts Anticipate Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) Will Announce Earnings of -$0.22 Per Share

Share on StockTwits

Equities research analysts expect Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) to report ($0.22) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Corbus Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.44) and the highest is $0.22. Corbus Pharmaceuticals posted earnings of ($0.21) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 4.8%. The firm is scheduled to report its next earnings report on Wednesday, August 14th.

On average, analysts expect that Corbus Pharmaceuticals will report full-year earnings of ($1.20) per share for the current financial year, with EPS estimates ranging from ($1.73) to ($0.61). For the next year, analysts expect that the business will report earnings of ($1.54) per share, with EPS estimates ranging from ($2.19) to ($0.95). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Corbus Pharmaceuticals.

Corbus Pharmaceuticals (NASDAQ:CRBP) last released its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.45). Corbus Pharmaceuticals had a negative return on equity of 166.99% and a negative net margin of 1,219.36%. The business had revenue of $1.89 million for the quarter, compared to the consensus estimate of $20.97 million.

A number of brokerages have recently commented on CRBP. Cantor Fitzgerald reiterated a “buy” rating and issued a $38.00 price target on shares of Corbus Pharmaceuticals in a research note on Tuesday, March 12th. ValuEngine lowered shares of Corbus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 28th. BidaskClub lowered shares of Corbus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, April 11th. Zacks Investment Research lowered shares of Corbus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, March 25th. Finally, CIBC began coverage on shares of Corbus Pharmaceuticals in a research report on Wednesday, March 20th. They set an “outperform” rating and a $28.00 price target for the company. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $23.59.

NASDAQ CRBP traded down $0.17 on Wednesday, hitting $6.68. 39,205 shares of the company’s stock were exchanged, compared to its average volume of 740,434. The business has a 50-day moving average price of $7.13. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.17. Corbus Pharmaceuticals has a 52 week low of $4.50 and a 52 week high of $9.11. The company has a market cap of $458.92 million, a PE ratio of -6.81 and a beta of 2.01.

A number of institutional investors have recently bought and sold shares of CRBP. Barclays PLC raised its stake in shares of Corbus Pharmaceuticals by 5,967.8% during the fourth quarter. Barclays PLC now owns 9,041 shares of the biopharmaceutical company’s stock valued at $52,000 after acquiring an additional 8,892 shares during the last quarter. BNP Paribas Arbitrage SA lifted its position in shares of Corbus Pharmaceuticals by 72,906.3% during the first quarter. BNP Paribas Arbitrage SA now owns 11,681 shares of the biopharmaceutical company’s stock worth $81,000 after purchasing an additional 11,665 shares in the last quarter. Prospera Financial Services Inc acquired a new stake in shares of Corbus Pharmaceuticals during the first quarter worth about $97,000. Cetera Advisor Networks LLC acquired a new stake in shares of Corbus Pharmaceuticals during the first quarter worth about $98,000. Finally, Metropolitan Life Insurance Co. NY lifted its position in shares of Corbus Pharmaceuticals by 357.7% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 16,973 shares of the biopharmaceutical company’s stock worth $99,000 after purchasing an additional 13,265 shares in the last quarter. 36.66% of the stock is owned by institutional investors and hedge funds.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase 3 clinical trial for the treatment of systemic sclerosis and dermatomyositis, and in Phase 2 clinical trial to treat systemic lupus erythematosus and cystic fibrosis.

Further Reading: Bollinger Bands

Get a free copy of the Zacks research report on Corbus Pharmaceuticals (CRBP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Equities Research Analysts’ Price Target Changes for July, 17th
Equities Research Analysts’ Price Target Changes for July, 17th
Trupanion Inc  Receives Average Recommendation of “Buy” from Analysts
Trupanion Inc Receives Average Recommendation of “Buy” from Analysts
MorphoSys AG  Receives Average Rating of “Hold” from Brokerages
MorphoSys AG Receives Average Rating of “Hold” from Brokerages
Brokerages Anticipate Calix Inc  Will Post Quarterly Sales of $99.95 Million
Brokerages Anticipate Calix Inc Will Post Quarterly Sales of $99.95 Million
Primas  Price Tops $0.0906
Primas Price Tops $0.0906
iShares S&P Mid-Cap 400 Growth ETF   Shares Down 0.2%
iShares S&P Mid-Cap 400 Growth ETF Shares Down 0.2%


 
© 2006-2019 Zolmax.